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Background
On July 15, 1997, two months after the World Health Assembly
(WHA) passed a resolution calling for the ‘‘global elimination of
lymphatic filariasis (LF) as a public health problem,’’ a small group
of public health leaders and scientists gathered at Magnetic Island,
near Townsville, Australia. They were meeting to consider the
elements of a program to achieve such a lofty goal. The evening
before the meeting began I asked several of those present, all
veterans of global efforts to eradicate smallpox, polio, or Guinea
worm disease, whether the LF elimination program should
concern itself with providing care to those who already suffer
the clinical manifestations of LF. Their response was uniformly
negative: LF elimination should focus solely on interrupting
transmission of the parasite. As with other disease eradication
efforts, the intended beneficiaries were future generations; saddling
the LF elimination program with responsibilities for clinical care
could dilute focus, divert resources, and complicate strategies and
partnerships.
Two days later, the group unanimously endorsed a ‘‘two-pillar’’
strategy that included both interrupting transmission and provid-
ing care for those with disease [1]. Several arguments had shifted
the group’s position. First, there was the ethical issue: how could
one ignore the suffering of 15 million people with lymphedema
and 25 million men with urogenital disease, principally hydrocele?
Hydrocele is readily treated with surgery, and evidence was
beginning to accumulate that simple measures, including hygiene
and skin care, could help arrest the progression of lymphedema
[2,3]. Second, the ‘‘public health problem’’ to which the WHA
resolution referred was clinical disease; by itself, the presence of
microfilaria in the blood does not constitute a public health
problem. In affected communities, clearing the blood of
microfilaria through annual mass drug administration (MDA)
can interrupt transmission of the parasite. However, the scientific
evidence remained divided on what effect, if any, these drugs have
on established disease [4]. Finally, and perhaps most importantly,
it was thought that providing care for those with filariasis-
associated morbidity could increase community acceptance of
MDA.
The World Health Organization (WHO) launched the Global
Programme to Eliminate Lymphatic Filariasis (GPELF) in 2000.
Ten years on, progress in scaling up MDA has been phenomenal;
496 million persons received antifilarial drugs in 2008 [5], yielding
impressive global health benefits [6]. In contrast, despite excellent
pilot programs (e.g., [7–9]) and some at the state and national
levels [10], morbidity management has generally languished.
What are the reasons for this imbalance? For one, the concerns
expressed at Magnetic Island had merit. The single focus of other
disease elimination programs enabled them to be streamlined and
efficient. The dual goals of interrupting transmission and
managing morbidity may require different approaches, skills,
and timeframes. Given limited resources and the ambitious goal of
interrupting transmission by 2020, MDA has taken priority.
Despite the experience of those who advocated a ‘‘two-pillar’’
strategy, there has been no scientific evidence that lymphedema
management actually improves acceptance of MDA. Thus, it has
been difficult to dispel the notion that investing in lymphedema
management drains limited resources from the primary goal of
interrupting transmission.
In this issue of PLoS Neglected Tropical Diseases, Paul Cantey and
colleagues elegantly demonstrate how program evaluation, at its
best, can both improve program effectiveness and contribute to
scientific knowledge. They provide the first solid evidence that
lymphedema management, far from competing with MDA,
actually enhances drug coverage [11]. The importance of high
coverage for interrupting LF transmission cannot be overstated;
indeed, success depends on it [12].
Findings
Following the 2008 MDA in Orissa, India, an area with
substantial morbidity, Cantey and colleagues used a well-accepted
cluster survey design to assess drug coverage and identify barriers
to compliance. The survey was meticulously conducted in three
areas where diethylcarbamazine (DEC) had been distributed 6–8
weeks previously. Residents of one area received the standard pre-
MDA education that is typical for Orissa (MDA-only). Another
area had enhanced community-based pre-MDA education that
was designed to address barriers to compliance identified in the
2007 MDA (Com-MDA) [13]. In the third area, which also
received enhanced community-based pre-MDA education, a
lymphedema management program had been initiated earlier in
the year (Com-MDA+LM). Patients and their families were
trained in basic lymphedema self-care and, interestingly, the public
also was educated as to the benefits of these measures for affected
persons.
The results were striking. In an area where compliance with
MDA chronically hovered around 50%, the proportion of survey
respondents who reported taking DEC was 52.9%, 75.0%, and
90.2%, respectively. Compliance was significantly higher in the
Com-MDA+LM area than in the Com-MDA area—and well
above the threshold considered necessary to interrupt transmission
[11]. Further, at the individual level, knowledge of at least one
component of lymphedema self-care was significantly and
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was observed even among those who did not have a family
member with leg swelling.
Implications
These provocative and encouraging findings raise important
questions for the GPELF and for further research. It is notable that
the work was done in India, the country with the greatest LF
burden. Can the results be replicated in other settings, in areas
with less intense morbidity or different economic conditions? To
what extent did they depend on a solid public–private partnership
that utilized the ample community connections and mobilization
skills of the private partner, the Church’s Auxiliary for Social
Action? What specific components of the lymphedema manage-
ment program had the greatest effect on drug coverage, and why?
The results both highlight the importance of lymphedema care
and suggest that community awareness of its availability and
benefits may be the key to increasing acceptance of MDA.
Future Directions
Scientific evidence that lymphedema management can enhance
MDA coverage and thereby hasten the interruption of LF
transmission comes at a critical juncture in the life of the GPELF.
In some countries, a boost in drug coverage provided by
lymphedema management could mean the crucial difference
between success and failure. This approach may be especially
effective in areas where systematic noncompliance with MDA has
been identified as a potential barrier to LF elimination [14].
In other countries, LF transmission appears to be on the verge
of elimination, and Ministries of Health will soon be seeking
official verification of this accomplishment. The imprecise wording
of the WHA resolution in 1997 served well for mobilizing a variety
of partners with different interpretations of the final endpoint,
ranging from reduced transmission to global extinction of the
parasite. Now, however, precise verification criteria are needed. It
would be inconsistent with the WHA resolution to verify
‘‘elimination as a public health problem’’ solely on the basis of
infection.
The findings of Cantey et al. will stimulate a fresh and vigorous
discussion regarding the relationship between the dual program-
matic goals of interrupting transmission and reducing current LF-
related suffering. They point the way toward a more comprehen-
sive LF program that is integrated into the health system [15] and
more fully equipped to truly eliminate LF as a public health
problem.
References
1. Seim A, Dreyer G, Addiss D (1999) Controlling morbidity and interrupting
transmission: twin pillars of lymphatic filariasis elimination. Revista da
Sociedade Brasileira de Medicina Tropical 32: 325–328.
2. Shenoy RK, Sandhya K, Suma TK, Kumaraswami V (1995) A preliminary
study of filariasis related acute adenolymphangitis with special reference to
precipitating factors and treatment modalities. Southeast Asian J Trop Med
Public Health 26: 301–305.
3. Dreyer G, Medeiros Z, Netto MJ, Leal NC, de Castro LG, et al. (1999) Acute
attacks in the extremities of persons living in an area endemic for bancroftian
filariasis: differentiation of two syndromes. Trans R Soc Trop Med Hyg 93:
413–417.
4. Addiss DG, Brady MA Morbidity management in the Global Programme to
Eliminate Lymphatic Filariasis: A review of the scientific literature. Filaria J 6:2.
Available: http://www.filariajournal.com/content/6/1/2.
5. World Health Organization (2009) Global programme to eliminate lymphatic
filariasis. Wkly Epidemiol Rec 84: 437–444.
6. Ottesen EA, Hooper PJ, Bradley M, Biswas G (2008) The global programme to
eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2:
e317. doi:10.1371/journal.pntd.0000317.
7. Brantus P (2009) Ten years of managing the clinical manifestations and
disabilities of lymphatic filariasis. Ann Trop Med Parasitol 103 (Suppl 1): S5–10.
8. Suma TK, Shenoy RK, Kumaraswami V (2002) Efficacy and sustainability of a
footcare programme in preventing acute attacks of adenolymphangitis in
Brugian filariasis. Trop Med Int Health 7: 763–766.
9. Addiss DG, Louis-Charles J, Roberts J, LeConte F, Wendt HM, et al. (2010)
Feasibility and effectiveness of basic lymphedema management in Leogane,
Haiti, an area endemic for bancroftian filariasis. PLoS Negl Trop Dis 4: e668.
doi:10.1471/journal.pntd.0000668.
10. Mathieu E, Amann J, Eigege A, Richards F, Sodahlon Y (2008) Collecting
baseline information for national morbidity alleviation programs: different
methods to estimate lymphatic filariasis morbidity prevalence. Am J Trop Med
Hyg 78: 153–158.
11. Cantey PT, Rout J, Rou G, Williamson J, Fox LM (2010) Increasing compliance
with mass drug administration programs for lymphatic filariasis in India through
education and lymphedema management programs. PLoS Negl Trop Dis 4:
e728. doi:10.1371/journal.pntd.0000728.
12. Stolk WA, Swaminathan S, van Oortmarssen GJ, Das PK, Habbema JD (2003)
Prospects for elimination of bancroftian filariasis by mass drug treatment in
Pondicherry, India: a simulation study. J Infect Dis 188: 1371–1381.
13. Cantey PT, Rao G, Rout J, Fox L (2010) Predictors of compliance with a mass
drug administration program for lymphatic filariasis in Orissa State, India, 2008.
Trop Med Int Health 15: 224–231.
14. Boyd A, Won KY, McClintock SK, Donovan CV, Laney SJ, et al. (2010) A
community-based study of factors associated with continuing transmission of
lymphatic filariasis in Leogane, Haiti. PLoS Negl Trop Dis 4: e640.
doi:10.1371/journal.pntd.0000640.
15. Gyapong JO, Gyapong M, Yellu N, Anakwah K, Amofah G, et al. (2010)
Integration of control of neglected tropical diseases into health-care systems:
challenges and opportunities. Lancet 375: 160–165.
www.plosntds.org 2 June 2010 | Volume 4 | Issue 6 | e741